PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES FOR MEDICATIONS DEVELOPMENT. POP: 9/20/2017-9/19/2022. N01DA-17-8935.
PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES FOR MEDICATIONS DEVELOPMENT. POP: 9/20/2017-9/19/2022. N01DA-17-8935.
批准号:
10285120
负责人:
DEBRA KELSH
金额:
$135.78万
依托单位:
--
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-20 至 2022-09-19
关键词:
Biological ProductsClinical PharmacologyClinical TrialsCocaineContractorDevelopmentDiseaseDrug KineticsEnzymesInpatientsInvestigationMolecularMonoclonal AntibodiesPharmaceutical PreparationsPhasePhase I Clinical TrialsPlacebosSafetyServicesTobacco useUnited States Food and Drug AdministrationVaccinescocaine usemarijuana usemethamphetamine usenovel therapeuticsopioid abuseopioid usepharmacokinetics and pharmacodynamicsstem
中文摘要
承包商应进行临床药理学/药代动力学研究,以支持开发治疗烟草、大麻、可卡因、甲基苯丙胺或鸦片类药物使用或滥用引起的疾病的新药。研究药物包括新分子实体、新生物制品(单抗、酶、疫苗等)、新药制品、以及经食品和药物管理局(FDA)批准用于其他适应症的药物制品。
英文摘要
Contractor shall carry out clinical pharmacology/pharmacokinetic studies to support the development of new medications for the treatment of disorders stemming from tobacco, cannabis, cocaine, methamphetamine, or opiate use or abuse. The study medications include new molecular entities, new biological products (monoclonal antibodies, enzymes, vaccines, etc.), new drug products, and drug products approved by the Food and Drug Administration (FDA) for other indications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金